Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

ePoster Display

764P - Survey on the practical implementation of BRCA gene and HRD-testing and PARP-inhibitor management in Germany: A national NOGGO/JAGO-AGO intergroup study

Date

16 Sep 2021

Session

ePoster Display

Topics

Genetic Testing and Counselling;  Cytotoxic Therapy;  Genetic and Genomic Testing

Tumour Site

Ovarian Cancer

Presenters

Joanna Baum

Citation

Annals of Oncology (2021) 32 (suppl_5): S725-S772. 10.1016/annonc/annonc703

Authors

J. Baum1, B.D. Nguyen2, P. Meyer-Wilmes3, A. Kreklau4, C. Buschmann5, S. Boz6, C. Fotopoulou7, R. Chekerov8, E.I. Braicu9, M. Hummel10, J. Sehouli11, K. Pietzner12

Author affiliations

  • 1 Gynecology Department, Charité Universitätsmedizin Berlin, 13351 - Berlin/DE
  • 2 Gynecology Department, University Hospital Zürich, 8091 - Zurich/CH
  • 3 Gynecology Department, University RWTH Aachen, 52074 - Aachen/DE
  • 4 Gynecology Department, University Hospital Leipzig, 04103 - Leipzig/DE
  • 5 Gynecology Department, University Hospital LMU Munich, 80337 - Munich/DE
  • 6 Project Management, NOGGO e.V., 13359 - Berlin/DE
  • 7 Gynecology Department, Hammersmith Hospital, Imperial College London NHS Trust, W12 0HS - London/GB
  • 8 Gynecology Department, Charité Universitätsmedizin Berlin, 13353 - Berlin/DE
  • 9 Tumor Bank Ovarian Cancer Network (toc) And Biostatistics, Charité Berlin, 13353 - Berlin/DE
  • 10 Department For Pathology, Charité Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 11 Department Of Gynecology, Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 12 Department Of Gynecology, Charité Universitätsmedizin Berlin, 13353 - Berlin/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 764P

Background

Since the introduction of Poly (ADP-ribose) polymerase inhibitors (PARPi) the Breast Cancer gene (BRCA)-testing has evolved as a standard management in high grade ovarian cancer (EOC). The purpose of the study is to analyze the current implementation of BRCA testing and PARPi therapy for EOC in Germany.

Methods

The questionnaire contained 40 questions covering real life data of genetic testing and the use of PARPi. It wasdivided into three main parts: 1. basic demographics of the respondents, 2. indication, counseling and selection of genetic testing, 3. approach of PARPi treatment. The questionnaire was distributed via mail from 14th August 2020 until 3rd May 2021. Statistics were descriptive.

Results

316 physicians participated in the survey. 54.9% were specialized in the field of gynecologic oncology and worked in a certified breast center (65.7%) and/or a gynecological cancer center (68.2%). 67.4% stated to test more than 80,0% of the primary EOC patients for BRCA mutation. The main reasons for failure of BRCA testing were patients` refusal (54.6%) and structural problems (31.7%). Regarding the patients` counseling on genetic testing, 86.3% stated high need for support. 21.5% performed an upfront germline and 5.2% a somatic test only, whereas 24.6% preferred both and 25.1% added a somatic test following a negative germline test. Only 23% of respondents would initiate HRD-testing. The most important criteria for selection of appropriate PARPi therapy were the side- effect profile (78.2%) and efficacy (71.2%). The patients´ request was relevant for only 11.2% of the participants.

Conclusions

Despite the high need for implication of BRCA gene testing and PARPi therapy adequate structure for routine BRCA/HRD testing and systematic education programs are needed. to prevent delay in family counseling and to prevent undertreatment of women with EOC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Charité Universitaetsmedizin Berlin.

Funding

AstraZeneca.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.